STOCKS TELEGRAPH

Tag: KZIA Stock Price

  • Kazia Therapeutics (KZIA) Rides High On New Research Findings

    Kazia Therapeutics (KZIA) Rides High On New Research Findings

    The stock value of Kazia Therapeutics Limited (NASDAQ: KZIA) had a significant increase in the most recent trading session, rising 92.19% to $10.10. This notable increase came after promising preclinical findings were published in the prestigious journal Molecular Cancer Therapeutics, which is affiliated with the American Association for Cancer Research.

    Paxalisib Could Revolutionize TNBC’s Business

    The recently released research focuses on the potential of paxalisib, Kazia’s primary experimental medicine, to transform the management of triple-negative breast cancer (TNBC), a highly aggressive and resistant cancer subtype.

    The study, which is headed by Professor Sudha Rao of the QIMR Berghofer Medical Research Institute, demonstrates how paxalisib can improve immune responses and change the tumor microenvironment. The medication showed synergistic anti-cancer benefits when used in conjunction with immune checkpoint inhibitors, which is encouraging as these immunotherapies become more popular in oncology.

    Combined Therapeutic Potential and Mechanistic Understanding

    One of the study’s main conclusions is that, in comparison to PI3K inhibition alone, combined inhibition of the PI3K and mTOR pathways is more effective at preventing tumor development and cell migration. Additionally, paxalisib was demonstrated to enhance CD4+ and CD8+ T cell infiltration and activation within TNBC tumors, highlighting its promise in immune-based cancer treatments.

    Paxalisib and pembrolizumab (KEYTRUDA) together decreased tumor burden and increased survival rates in preclinical animals, confirming the usefulness of this combination therapy approach.

    Advancements in Clinical Use

    These results have set the stage for Kazia’s newly launched Phase 1b clinical study, which will assess paxalisib in patients with advanced breast cancer in conjunction with checkpoint inhibitors and chemotherapy. An important step in converting preclinical promise into clinical benefit is this experiment.

    According to Kazia, this result enhances paxalisib’s therapeutic potential beyond brain malignancies and places it as a top contender for next-generation immunotherapy for solid tumors.

    “Combination of the PI3K/mTOR inhibitor paxalisib with immune checkpoint inhibitors enhances antitumor activity in preclinical models of triple-negative breast cancer,” states the study, which provides a strong basis for additional clinical investigation.

  • Kazia Therapeutics Limited (KZIA) stock soared in the after-hours trading session; find out why

    Kazia Therapeutics Limited (KZIA) stock soared in the after-hours trading session; find out why

    Kazia Therapeutics Limited (KZIA) stock recently plunged by 1.33% to trade at $11.12. It previously closed at $11.27. However, in the after-hours trading session, the KZIA stock soared higher than 24%.

    The stock movement pattern does not have any newly announced press release or expressed external factor motivating it. So why is there a surge in the after-hours trading session? For this we will have to connect the dots of the company’s previously announced news of licensing agreement as well as the type of ownership in the KZIA stock.

    Recent developments in KZIA stock

    Kazia Therapeutics Limited (KZIA) is a biotechnology company specifically focusing on innovative oncology. The company is based in Barangaroo, Australia. KZIA’s operational bases include working on developing therapies for numerous oncology indications. Furthermore, its lead program is known as paxalisib, which is being developed as a treatment for glioblastoma. Glioblastoma is the most aggressive and primary form of brain cancer in adults.

    Licensing agreement with the ovarian-cancer research expert Oasmia

    On 2nd March 2021, Kazia announced its exclusive worldwide agreement to license Cantrixil to Oasmia Pharmaceutical AB. Cantrixil is a clinical stage, uniquely innovated drug candidate that is being developed for the treatment of ovarian cancer.

    The agreement constitutes of Oasmia making a transactional payment of $4 million to Kazia, double digit royalties on commercial sales and upto $42 million payment on each progress completion milestone.

    Oasmia has worked over the years to harness deep expertise in the field of ovarian cancer and has worked on similar project of its own like Cantraxil which led to the development of lead product Apealea. Overall progress on the commercial production and development of Cantraxil is major forward step news since the clinical proof of the drug’s concept. This is solid clinical-stage progress on which investors can hedge their bets.

    How is type of shareholder influencing stock movement?

    Now let us focus on the investors and the type of shareholders who own KZIA stock.

    According to ownership breakdown, the institutions hold majority of the shares in the KZIA stock. This shows that the stock management is owner-oriented. When many institutions hold a fair amount of stake in a stock, it usually suggests that the company is well-established, major possibility of inside ownership and has a certain degree of credibility.

    While this could all turn to flip-side if the institutions altogether change their perspective or react to negative news about the company’s fundamental dynamics. But right now, mainly institutional and insider ownership is what is hinting towards the stock’s recent positive movement; it depicts that institutions are satisfied with the current leadership of the management and their preferences are being met.